Press Release

ProJenX Announces Removal of Partial Clinical Hold for Prosetin Program by FDA

Immunitas Therapeutics to Present Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting

ProJenX Receives European Authorization for First Study of Prosetin in People Living with ALS

Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead

Immunitas Therapeutics Appoints Annalisa D’Andrea, Ph.D., as Chief Scientific Officer

Pleno Deploys its RAPTOR Instrument Platform Available with TotalSeq™ Antibodies from BioLegend

ProJenX Announces Initial Closing of $15M Series A Financing and Appoints Rick Hartz to Board of Directors

Immunitas Therapeutics Presents Data for Novel Anti CLEC2D-TLR9 Conjugate Program at the Society for Immunotherapy of Cancer 2023 Annual Meeting

AVILAR THERAPEUTICS TO PRESENT NEW DATA FOR ATAC EXTRACELLULAR PROTEIN DEGRADERS AT TARGETED PROTEIN DEGRADATION SUMMIT

FDA Grants Fast Track Designation to ANPD001, Autologous Investigational Cell Therapy for the Treatment of Parkinson’s Disease